Avidity Biosciences
RNA
$24.36
Share price
2.22%
Change (1 day)
40.48%
Change (1 year)
Categories
Avidity Biosciences (RNA) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.12 B
According to Avidity Biosciences's latest financial reports the company's total liabilities are $0.12 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Avidity Biosciences - Total liabilities on balance sheet (from 2019 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.12 B | 110.44% |
| 2022-12-31 | $60.72 M | 31.58% |
| 2021-12-31 | $46.15 M | 66.76% |
| 2020-12-31 | $27.67 M | -82.94% |
| 2019-12-31 | $0.16 B | 259.7% |
| 2018-12-31 | $45.11 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $137.21 B | 107,272.98% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $58.82 B | 45,932.43% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $2.40 B | 1,782.17% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $2.71 B | 2,023.98% | 🇺🇸 USA |
 Fate Therapeutics
FATE | $0.13 B | 7.83% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $0.30 B | 140.54% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | $82.23 M | -35.65% | 🇺🇸 USA |